Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
Yonsei University · Yonsei University Health System · +26 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
601
total citations
- FWCI
- 144.70
- Percentile
- 100%
- References
- 22
Citations per year
Authors
226- SYSun Young RhaCorresponding
Yonsei University, Yonsei University Health System
- DODo‐Youn Oh
Seoul National University Hospital
- PYPatricio Yañez
Universidad de La Frontera
- YBYuxian Bai
Harbin Medical University, Third Affiliated Hospital of Harbin Medical University
- MRMin‐Hee Ryu
Ulsan College, Asan Medical Center, University of Ulsan
Topics & keywords
Topics
Keywords
- Medicine
- Internal medicine
- Clinical endpoint
- Capecitabine
- Chemotherapy
- Placebo
- Population
- Pembrolizumab
No related works found for this paper.